Levacetylleucine

Name: Levacetylleucine
Brand: MedChemExpress
SKU: HY-59291
Rating: 4.5 (1 reviews)

Cat. No.: HY-59291 Purity: ≥98.0%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Levacetylleucine, an orally bioavailable and brain-penetrant endogenous metabolite, is an acetylated derivative of amino acid leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention.

For research use only. We do not sell to patients.

Levacetylleucine Chemical Structure

CAS No. : 1188-21-2

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 55	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 55	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
1 g	USD 60	In-stock	Estimated Time of Arrival: December 31
5 g		Get quote
10 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Human Endogenous Metabolite

In Vivo

Levacetylleucine (60 mg/kg, i.v., administration on days 1, 2 and 3 for 15 days) decreases the postural imbalance scores and accelerates the course of postural compensation induced by UL in rats^[3].
Levacetylleucine (100 mg/kg, oral gavage, administration daily for 28 days) attenuates cortical cell death afer traumatic brain injury (TBI) in N-Acetyl-L-leucine-treated TBI mouse cortices^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (mean 400±20 g, age 3 months) after chemical UL^[3]
Dosage:	60 mg/kg
Administration:	i.v., 15 days
Result:	Significantly decreased the postural imbalance scores on 7 day and accelerated the course of postural compensation by about 6 days in rats.

Animal Model:	C57/BL6 mice^[4]
Dosage:	100 mg/kg
Administration:	oral gavage, administration daily for 1-28 days
Result:	Did not afect food intake and body weight in mice.

Animal Model:	N-Acetyl-L-leucine-treated TBI mouse cortices^[4]
Dosage:	100 mg/kg
Administration:	oral gavage, administration daily for 28 days
Result:	Prevented cortical cell death which peaks at early time points (day 1) afer TBI in N-Acetyl-L-leucine-treated TBI mouse cortices.

Molecular Weight

173.21

Formula

C₈H₁₅NO₃

CAS No.

1188-21-2

Appearance

Solid

Color

White to off-white

SMILES

CC(C)C[C@H](NC(C)=O)C(O)=O

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (577.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.7733 mL	28.8667 mL	57.7334 mL
5 mM	1.1547 mL	5.7733 mL	11.5467 mL
10 mM	0.5773 mL	2.8867 mL	5.7733 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (14.43 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (276 KB) SDS (393 KB)

COA (250 KB) HNMR (197 KB)

Handling Instructions (2659 KB)

References

[1]. Bremova-Ertl T, et al. Trial of N-Acetyl-l-Leucine in Niemann-Pick Disease Type C[J]. N Engl J Med. 2024 Feb 1;390(5):421-431. [Content Brief]

[2]. Sarkar C, et al. N-acetyl-L-leucine: a promising treatment option for traumatic brain injury[J]. Neural Regen Res. 2022 Sep;17(9):1957-1958. [Content Brief]

[3]. Günther L, et al. N-acetyl-L-leucine accelerates vestibular compensation after unilateral labyrinthectomy by action in the cerebellum and thalamus[J]. PLoS One. 2015 Mar 24;10(3):e0120891. [Content Brief]

[4]. Hegdekar N, et al. N-Acetyl-L-leucine improves functional recovery and attenuates cortical cell death and neuroinflammation after traumatic brain injury in mice[J]. Sci Rep. 2021 Apr 29;11(1):9249. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.7733 mL	28.8667 mL	57.7334 mL	144.3335 mL
	5 mM	1.1547 mL	5.7733 mL	11.5467 mL	28.8667 mL
	10 mM	0.5773 mL	2.8867 mL	5.7733 mL	14.4333 mL
	15 mM	0.3849 mL	1.9244 mL	3.8489 mL	9.6222 mL
	20 mM	0.2887 mL	1.4433 mL	2.8867 mL	7.2167 mL
	25 mM	0.2309 mL	1.1547 mL	2.3093 mL	5.7733 mL
	30 mM	0.1924 mL	0.9622 mL	1.9244 mL	4.8111 mL
	40 mM	0.1443 mL	0.7217 mL	1.4433 mL	3.6083 mL
	50 mM	0.1155 mL	0.5773 mL	1.1547 mL	2.8867 mL
	60 mM	0.0962 mL	0.4811 mL	0.9622 mL	2.4056 mL
	80 mM	0.0722 mL	0.3608 mL	0.7217 mL	1.8042 mL
	100 mM	0.0577 mL	0.2887 mL	0.5773 mL	1.4433 mL